Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

89Zr˗DFO˗REGN5054

Radiopharmaceutical · developed by Regeneron Pharmaceuticals

Phase 1 Most advanced trial
REGN Developer

What is 89Zr˗DFO˗REGN5054?

89Zr-DFO-REGN5054 is a zirconium-89 radiolabeled agent, linked through the chelator desferrioxamine (DFO), built on the REGN5054 molecule.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Radiopharmaceutical
Therapy area
Oncology
Developer
Regeneron Pharmaceuticals (REGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

Advanced Solid TumorMetastatic Solid Tumor

More from Regeneron Pharmaceuticals

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the REGN page.

Follow REGN, the company behind 89Zr˗DFO˗REGN5054

See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

REGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.